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In recent articles,1,2 we discussed a fun-
damental shift in the way in which poly-
microbial infections can be viewed. In 
these articles, we used chronic bacterial 
infections of the lower airways, and spe-
cifically those that occur in cystic fibrosis 
(CF) patients, as a model system. These 
infections are of course critical in clinical 
terms for these patients; respiratory fail-
ure due to a combination of these chronic 
infections with the host immune response 
that they elicit remains the leading cause 
of mortality in CF. Given the impor-
tance of maintaining lung health in these 
patients, the CF airways are the focus of a 
wide range of scientific and clinical stud-
ies. In particular, research momentum 
has built in relation to identifying the 
microbes present in the CF lung. Already, 
many important insights have been gained 
through the application of increasingly 
sophisticated culture-independent analyt-
ical methodologies to identify all micro-
bial nucleic acids in the CF lung,3-6 and 
those from viable or metabolically active 
bacteria.7,8 In doing so, the data generated 
have revealed microbial assemblages of far 
greater diversity and in turn complexity 
than has previously been recognised in this 
context. These studies, which have served 
to highlight the inadequacy of traditional 
culture-based diagnostic microbiology to 
fully characterise such infections,9 have 
also led to a significant shift in our view 
of what the word “infection” represents 
for these and other chronic diseases, with 
potentially important implications for 
their optimal treatment. In this article 
we contrast the information we and oth-
ers have accrued from chronic lung infec-
tions with data generated from studies 
examining the microbial communities 
present in the gut. In doing so we high-
light parallels between these two contexts 
and discuss how these commonalities can 
inform clinical thinking.
Common Beginnings
The process of isolating microbes through 
enrichment culture was developed in the 
19th century, and culture-based strategies 
remain the basis of diagnostic bacteriology 
to this day. Whilst there was recognition 
that certain infections were in fact poly-
microbial in nature at the beginning of 
the 20th century,10,11 there existed neither 
the theoretical basis on which to construct 
models of polymicrobial activity, nor the 
tools to dissect these systems well.
In a diagnostic context, culture-based 
microbiology relies on the detection of 
aetiological agents by providing the con-
ditions that a given species requires for 
growth in vitro. In many cases, even where 
the involvement of a specific pathogen is 
suspected, the provision of such suitable 
growth conditions can be extremely diffi-
cult. This problem is further compounded 
when diseased tissues contain multiple 
microbes, challenging the association of 
a single species with a particular clinical 
condition. In such circumstances, the size 
of the pool of uncharacterised species, and 
the relative distribution of those species 
within that pool, may not easily be deter-
mined using culture-based approaches. To 
illustrate, culture-independent surveys of 
phylogenetically-informative ribosomal 
RNA genes have indicated that more than 
75% of the phylotypes detected in the 
human large intestine do not correspond 
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species that were both amenable to labo-
ratory cultivation and considered to have 
important roles in CF lung disease.24 Of 
these, the most notable were Pseudomonas 
aeruginosa, Burkholderia cepacia com-
plex, Staphylococcus aureus, Haemophilus 
influenzae, Alcaligenes xylosoxidans 
and Stenotrophomonas maltophilia.25,26 
However, the use of molecular techniques 
has shown a far greater range of bacterial 
species to be present (and abundant) in 
CF respiratory samples than was previ-
ously appreciated,3-6 and the use of careful 
culture techniques not commonly used in 
the clinical arena has corroborated these 
findings.27
Whilst it is difficult to succinctly 
describe the taxonomy of such a wide 
diversity of species, to give some insight, 
the traditionally recognised CF patho-
gens fall into two phyla; Proteobacteria 
(H. influenzae, P. aeruginosa, S. malto-
philia, B. cepacia complex, A. xylosoxidans) 
and Firmicutes (S. aureus). Culture-
independent studies have also shown CF 
secretions to be abundant in other mem-
bers of these phyla, including species of 
the genera Veillonella, Streptococcus, 
Abiotrophia and Gemella (Firmicutes), 
and Neisseria and Acinetobacter 
(Proteobacteria). Culture-independent 
studies have further shown however that 
species belonging to four other phyla are 
also commonly resolved: Actinobacteria 
(including Actinomyces spp., Rothia spp.), 
Bacteroidetes (including Prevotella spp., 
Porphyromonas spp., Capnocytophaga 
spp.), Spirochaetes (Treponema spp.) and 
Fusobacteria (Fusobacterium spp.).
A common but unexpected finding 
in adult CF respiratory samples has been 
the high relative representation of species 
requiring anaerobic conditions for growth, 
such as those in the genera Veillonella and 
Prevotella.9,27 The presence in CF secre-
tions of bacteria with diverse growth 
requirements is however less surprising 
once the biology of the CF respiratory 
tract has been considered. The CF airways 
have been found to be both chemically 
and physically diverse, containing com-
plex nutrients and carbon sources.28 Levels 
of important factors required for growth 
by some species, such as iron,29 and carbon 
sources such as mucin and alginate,30,31 and 
amino acids,32 vary in concentration across 
method, primers are used that amplify 
regions of particular phylogenetically 
informative genes that are conserved across 
the Domain Bacteria, in theory producing 
PCR product for any bacterial species rea-
sonably abundant within a sample. The 
key to this process is that, between the two 
conserved regions recognized by the prim-
ers, there is sufficient sequence variation 
among different bacteria to enable spe-
cies discrimination and identification. As 
such, this method provides a basis for the 
characterisation of bacterial species pres-
ent within a clinical sample without the 
need for prior prediction of which species 
may be present, addressing many of the 
drawbacks of both culture-based assays 
and species-specific PCR.
By far the most commonly used region 
in such ‘broad-range PCR’ strategies is the 
16S ribosomal RNA (rRNA) gene.19 PCR 
primers are targeted towards regions of 
the 16S rRNA gene that show conserva-
tion across the Domain Bacteria, mean-
ing that a broad range of ribosomal gene 
products are generated from DNA tem-
plates extracted from a mixed bacterial 
community. To resolve this mixture of 
gene products and to identify the indi-
vidual species present in the community, a 
number of strategies can be applied. These 
include Single Strand Conformation 
Polymorphism, Denaturing Gradient Gel 
Electrophoresis, Temperature Gradient 
Gel Electrophoresis, Terminal Restriction 
Fragment Length Polymorphism 
(T-RFLP) profiling and 16S rRNA gene 
sequencing (reviewed in refs. 20–22). 
Each technique exploits the variable inter-
nal regions directly or indirectly, with 
the strategy used selected on the basis of 
the clinical question and the type of data 
required.20,22 Such broad-range strate-
gies are finding increasing use, and in an 
expanding range of clinical scenarios.23
Concepts Emerging from the CF 
Airways
As highlighted in earlier publications, the 
application of molecular techniques to the 
analysis of CF airway infections has sig-
nificantly changed the way in which such 
infections are viewed. Traditional culture-
based diagnostic microbiology focused 
on a relatively small number of bacterial 
closely to cultured species.12-14 In addition, 
any analysis based on obtaining species in 
axenic culture does not afford any insight 
into the interactions between the microbes 
present in a tissue, or consequently into the 
impact that these interactions may have. 
For these reasons, the rational characteri-
sation of highly diverse microbial systems, 
and their relationship with disease patho-
genesis, using traditional culture-based 
techniques is severely hampered.
Molecular Advances
The development of polymerase chain-
reaction amplification (PCR) provided 
a basis for assays that exploit differences 
between species at the nucleic acid level. 
Here, variation in DNA sequence, partic-
ularly the presence of nonconserved genes, 
can be used to derive species-specific PCR-
based assays. These techniques are applied 
directly to nucleic acids extracted from 
clinical samples to determine whether par-
ticular species are present, often quantita-
tively using real-time PCR.15 In all such 
culture-independent analyses, the first step 
is the extraction of nucleic acids directly 
from specimens of interest. As such, these 
methods avoid many of the biases associ-
ated with in vitro culture. However, as with 
any process however, nucleic acid extrac-
tion can introduce other forms of analyti-
cal biases, such as through differential lysis 
of cells of different bacterial species.16,17 
Nevertheless, such species-specific assays 
enable direct bacterial detection in a wide 
range of samples, with the popularity of 
this approach reflected in the ever increas-
ing number of such assays.18 Nevertheless, 
whilst conferring advantages in terms 
of speed, cost and accuracy, these assays 
share some of the drawbacks associated 
with the use of selective media in culture-
dependent approaches. Again, application 
of these methods requires a prediction to 
be made as to which agents are likely to 
be associated with a particular sample, so 
that the required reagents (e.g., the appro-
priate growth medium or species-specific 
primers) are used. They also share, even 
with automation, a practical upper limit to 
the number of species-specific assays that 
can be performed on one sample.
Alternatives to species-specific 
approaches are available. In one  PCR-based 
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As might be expected when comparing 
pathogenic and non-pathogenic systems, 
there are a number of clear differences. 
In CF, the presence of high densities of 
bacteria in an area of the body normally 
free from large-scale microbial colonisa-
tion is associated with consequences that 
can be assumed to be wholly negative. By 
contrast, the presence of a complex micro-
biota in the gut has a number of important 
functions ranging from supply of nutrients 
to the host, immune system development, 
angiogenesis and fat storage.60-67 Rather 
than representing a pathogenic system, 
the relationship between the gut microbi-
ota and the host is assumed to be typically 
symbiotic.
However, the relationship between 
the host and the microbial community in 
the CF lung, and that between the host 
and the normal gut microbiota, may rep-
resent opposite ends of a continuum of 
pathogenicity (Fig. 1). Further, this is 
a spectrum onto which all microbiota at 
all colonised sites of the body fall. In this 
scheme, the normally symbiotic relation-
ship between the host and the gut micro-
biota can occasionally become unbalanced 
(a phenomenon referred to as dysbiosis), 
as with the introduction of new pathogens 
or antibiotics,68 in some cases resulting in 
precipitation of disease. Whilst CF airway 
disease is characterised by acute periods of 
pulmonary exacerbation in which the rela-
tionship between the host and infecting 
microbial community is considered highly 
pathogenic, in much of the intervening 
periods the relationship is of relatively low 
pathogenicity, referred to as periods of 
stability, with exacerbations perhaps pre-
cipitated by new viral infections or other 
perturbing factors.69
These commonalities between the gut 
and the CF lung are reflected in a number 
of significant similarities in the behavior 
of their microbial systems. One example 
is the social interaction between microbial 
community members, exemplified among 
colonising bacteria by the expression of 
quorum sensing mediated behaviors such 
as biofilm formation, which is important 
for bacterial colonisation in both con-
texts.70,71 Other quorum-sensing-mediated 
behaviors that are also key to infection, 
such as the expression of virulence fac-
tors, have also been shown to be exhibited 
in the CF lung is essential if the drive to 
understand and treat this disease is to be 
fully effective.
Insights from Studies  
of the Intestinal Microbiota
Infections in the CF airways were initially 
selected as a model system for applying 
molecular techniques to complex microbial 
communities based on a number of factors. 
These included the clinical importance of 
the condition and the assumption that 
the bacterial assemblages involved would 
be comparatively simple (as suggested 
by conventional culture-based analysis). 
However, as the true complexity of the 
CF airway microbiota started to emerge, 
parallels with highly complex microbial 
systems found in other areas of the body 
have become increasingly apparent.
The gut microbiota represents a sig-
nificant difference in scale and complexity 
compared with that in the CF lung; 16S 
ribosomal RNA gene analysis has led to 
estimations that the gastrointestinal (GI) 
microbiota consists of hundreds of gen-
era and thousands of bacterial species.46-48 
This complexity confounds the use of 
conventional culture-based analysis, and 
makes this context an ideal candidate 
for culture-independent analysis of the 
community.48 Over the past decade these 
techniques have given a substantially 
broader and more accurate view of the gut 
microbiota.49,50 The relatively high costs of 
large scale 16S rRNA dideoxynucleotide 
sequencing has limited its use in such 
systems and, as is the case with the CF 
airways, studies have utilised community 
profiling approaches such as T-RFLP51,52 
and denaturing gradient gel electrophore-
sis (DGGE)53-55 to ascertain overall com-
munity structure and track its dynamics. 
More recently, the wider applicability 
of pyrosequencing, combined with the 
highly abundant data that it is able to pro-
vide, has led to an expansion of the use of 
this approach to the analysis of microbes 
that colonise the gut.56-59
Comparisons of the microbial systems 
in the gut and the CF lung may help to 
distinguish factors that underpin the 
typically mutually beneficial relation-
ships usually found in the GI tract from 
the injurious relationships in the CF lung. 
the airways, as do electron acceptors such 
as oxygen and nitrogen oxides.33,34 As such, 
this heterogeneity provides conditions that 
are potentially suitable for colonisation by 
a wide range of microorganisms.
It is important to also recognise that the 
diversity seen in the CF lung is not only 
reflected in the number of bacterial spe-
cies present, but also in their relative abun-
dance. This distribution of bacterial cell 
numbers between species within the lung 
may be ecologically important in terms of 
interactions between different community 
members. There is also diversity at bacte-
rial sub-species levels, as exemplified by 
the co-occurrence of multiple strains of 
P. aeruginosa.35,36 Furthermore, the diver-
sity observed among microbes is not lim-
ited to bacteria, but extends, for example, 
to viruses37 and to fungi.38 Whilst of an 
apparently lesser magnitude, the microbial 
diversity seen in the CF lung is reminiscent 
of the microbial communities normally 
found in other areas of the body, such as 
the oral cavity or gut. As such, in keep-
ing with the terminology used to describe 
those polymicrobial communities, the 
diverse system seen in the CF lung may 
also be regarded as a “microbiota”.
Microbial diversity in turn leads to 
the potential for “social interactions”,39-43 
that may in turn dampen or exaggerate 
outcomes in relation to pathology and 
response to therapy. In work examining 
the bacterial communities that colonise 
the oral cavity, Jenkinson and Lamont44 
raised the possibility that, through social 
interactions, a microbial community may 
itself represent a pathogenic entity. There 
is mounting evidence that this concept 
may also be true as applied to the microbes 
in the CF lung. Sibley et al.45 demon-
strated that the virulence of known CF 
pathogens, such as P. aeruginosa, can be 
increased significantly by the presence of 
species previously dismissed as clinically 
insignificant, such as those derived from 
the oral cavity. We have therefore proposed 
that the aggregate microbial content of the 
CF lung might usefully be considered as 
a distinct pathogenic entity, whose impact 
on the host may be greater than the com-
bined impacts of its individual component 
species alone.2 In light of this concept, 
constructing a detailed and comprehen-
sive model of the polymicrobial system 
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studies indicate that Staphylococcus aureus 
and non-encapsulated H. influenzae are 
isolated early in life, whereas most CF 
patients become infected with P. aerugi-
nosa over time.90 In a previous article, we 
described the use of culture-independent, 
T-RFLP analysis of bronchoalveolar lavage 
fluid (BALF) samples from sputum-
producing paediatric patients. The data 
derived showed that there were no signifi-
cant differences in diversity between the 
bacterial communities detected among 
samples from young children with CF and 
those from CF adults.91 Further, Harris et 
al.92 applied 16S ribsomal RNA gene clone 
sequence analysis to the characterisation 
of bacteria in BALF from non-sputum and 
sputum producing children at single time 
points. This process identified a total of 65 
different bacterial species (including the 
traditionally recognised CF pathogens) 
in BALF sampled from 28 children with 
a mean age of 8 years. These data suggest 
that, even in the paediatric CF airways, the 
bacterial diversity is significantly higher 
than previously recognised. As such, 
application of further metagenomic analy-
sis will greatly enhance our understanding 
of the progression of microbial colonisa-
tion and infection of the CF airways, the 
processes that drive this progression, and 
why some species are able to persist in this 
niche whilst others are not.
The Influence of Microbiota  
on Known Pathogens
“Colonisation resistance” is a term used 
to describe the phenomenon whereby 
pathogenic species are excluded from a 
region of the body, such as the gut, by the 
presence of a microbiota.93 This exclusion 
may be due to a range of factors, includ-
ing changes in oxidation-reduction 
potential and pH,94 elaboration of inhibi-
tory substances (e.g., bacteriocins, fatty 
acids, hydrogen sulfide),94,95 competition 
for nutrients,95 and competition for adhe-
sion sites.96 Specific examples include the 
competition for proline with indigenous 
Escherichia coli that has been shown to 
limit growth of E. coli O157:H7 in the 
intestines of mice,97 and the age-asso-
ciated changes in gut microbiota that 
have been correlated with increased risk 
of C. difficile infection.98 Interestingly, 
niche physiology,81 as well as the range 
of environmental microbes that an indi-
vidual is exposed to.82,83 Determining the 
reasons for such differences will require 
further in depth study; however, some 
clues may help to elucidate the manner in 
which these microbiota develop.
The temporal progression of the gut 
microbiota in neonates has been investi-
gated through metagenomic analysis, with 
evidence emerging of an ordered progres-
sion toward the microbial communities 
found in the guts of adults.84,85 Whilst 
microbial communities varied widely from 
infant to infant in their composition, the 
distinct features of the microbial commu-
nity of each infant were recognizable for 
intervals of weeks to months. Whilst still 
distinct, a convergence toward a profile 
characteristic of the adult gastrointestinal 
tract was observed by the end of the first 
year of life.85 Further analysis of these data 
by Trosvik et al.86 suggested the conver-
gence observed is driven, in the main, by 
simple, phylum-level interactions between 
colonising species. Further, interactions 
between the gut microbiota and the host 
during this process of development may be 
key to the emergence of the adult intesti-
nal immune system,87,88 also reviewed by 
Guarner et al.89
While such detailed analysis of the tem-
poral progression of airway colonisation in 
CF is yet to be performed, recent work has 
exposed the complexity of microbial com-
munities in the airways of young children 
with CF, and there is evidence of species 
succession in this context. Culture-based 
by bacteria in both chronic respiratory 
infections,72,73 and the gut.74,75 Whilst the 
impact of such coordinated behavior on 
both virulence and drug impact is well 
recognised in the CF lung, it has been the 
focus of less intense study in the gut to 
date. However, in common with the CF 
lung, the virulence of clinically important 
pathogens in the gut has been shown to be 
modulated by other members of the bacte-
rial community. For example, the synthe-
sis of Shiga toxin by enterohaemorrhagic 
Escherichia coli O157:H7 has been shown 
to be inhibited by factors secreted by other 
members of the intestinal microbiota.76
The Developing Microbiota
Once established, the microbiota associ-
ated with a particular region of the body, 
such as the gut, is relatively stable in terms 
of its composition within individuals com-
pared to the levels of variation in micro-
bial constituency among different niches 
or among the same niches in different 
individuals.77 Further, data derived from 
the study of murine models and humans 
suggest that, following challenge such as 
antibiotic treatment, these microbiota will 
largely revert to their pre-perturbation 
state,68,78 provided that perturbation is not 
too severe.79,80 Data derived from analysis 
of the CF lung suggest a comparable situ-
ation (data not shown). By comparison, 
differences that are seen when comparing 
the same microbiota from body sites in 
different individuals are likely to reflect a 
range of factors, including host genetics,65 
Figure 1. the relative positions of the interactions between the host and the microbial com-
munity in stable and exacerbating cF pulmonary disease, and in the healthy and dysbiotic gut, on 
a conceptual continuum of pathogenicity.
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has shown that a significant proportion 
of the proteins found in faeces is involved 
in innate immune defense, indicating an 
extensive effort by the host to regulate the 
microbial population.118 The intestinal 
microbial balance may also be temporar-
ily changed by an alteration in diet,119 in 
turn linked to an impact on memory and 
anxiety-like behavior.120
Evidence of such a complex interre-
lationship between the gut microbiota 
and the host has implications for the 
fundamental ways in which we consider 
CF lung infections. They present the 
possibility that a microbial community 
may impact not only the host tissues 
with which it is in direct contact, but 
also physically and functionally distant 
areas of the body. This raises important 
considerations both for the way in which 
exacerbations of chronic infections may 
be triggered, and for the effects of the 
antimicrobial therapies commonly used 
in their treatment.
Disruption of the symbiotic relation-
ship between the gut microbiota and the 
host has been implicated in serious dis-
eases, such as ulcerative colitis, irritable 
bowel syndrome and Clostridium difficile 
colitis,113,121,122 and as reviewed by Peterson 
et al.114 If the gut model is translated to 
the CF respiratory tract, a context where 
any colonising bacterial community is 
likely abnormal and highly pathogenic, 
the question can be asked: can a balance 
between the host and the infective bacte-
rial community in CF be achieved that 
results in a reduction in pathogenicity? 
For example, are there bacterial commu-
nities that may be associated with mini-
mal pathogenesis? Are there treatments, 
such as probiotics, nutrients, or other 
chemicals, that would favor such “benefi-
cial” communities? This concept may be 
controversial given the presumed highly 
deleterious impact of airway colonisation. 
However, in light of the current lack of 
microbiological explanation for the tran-
sition between periods of increased and 
decreased symptoms, and the common use 
but only limited efficacy of antimicrobial 
strategies designed to significantly disrupt 
this polymicrobial community, this is a 
possibility that warrants consideration. 
Further, there is evidence that, as airway 
disease progresses, primary colonising 
develop disease but harbours an infective 
organism that may cause disease in others. 
This phenomenon is exhibited in the GI 
tract by both Neisseria meningitidis and 
Vibrio cholerae, with great clinical signifi-
cance.108,109 Similarly, lung infection with 
nontuberculous mycobacteria can cause 
substantial decline in lung function in 
some, but not all, people with CF.110 An 
example of a mechanism for such varia-
tion in pathogenicity within individual 
microbial species is the ability of some 
pathogenic bacteria to turn on or off viru-
lence genes depending on circumstance, 
as with the production of exotoxins by 
Clostridium difficile.111 Moreover, where 
pathogenicity is conferred by the expres-
sion of discrete traits, the potential influ-
ence of co-infecting species to affect this 
expression of pathogenesis is clear. In 
vitro evidence for the potential for clini-
cally relevant polymicrobial interactions 
in the CF lung comes from Sibley et al.45 
who demonstrated that pathogenically 
important behaviors of P. aeruginosa can 
be impacted by the presence of bacterial 
species that are routinely disregarded by 
most treating clinicians.
Host-Microbiota Interactions
As discussed above, once established, 
the gut microbiota is typically character-
ised by a symbiotic relationship with the 
host. The impacts of this interaction can 
be far-reaching and profound. The gut 
microbiota can impact host metabolism 
and energy storage, with the breakdown 
of this symbiotic relationship implicated 
in the development of obesity and type 
2 diabetes,112 as well as conditions such 
as irritable bowel syndrome (IBS)113 and 
inflammatory bowel disease.114 Further, 
as discussed by Lyte,115 microbes both 
produce and recognise neuroendocrine 
hormones, potentially allowing for direct 
signalling with the host. This capacity may 
be manifested in the suggested association 
between changes in the composition of 
gut microbes and changes in the normal 
functioning of the nervous system,116 and 
further, between gut dysbiosis and changes 
in host behavior.113,117
The relationship between the gut 
microbiota and the host also appears to 
be bi-directional. Metaproteomic analysis 
the interaction between the host and 
the gut microbiota can be exploited by 
certain enteropathogenic bacteria in 
order to overcome colonisation resis-
tance. The presence of species such as 
Citrobacter rodentium and Salmonella 
enterica in the gut triggers a inflamma-
tory host response. The resulting pro-
duction of antimicrobial peptides by the 
host affects the composition of the gut 
microbial community and suppresses its 
growth, allowing the pathogenic species 
to become established.99-101
Disruption of gut microbiota through 
the use of antibiotics can also change 
its composition, potentially facilitating 
pathogenic behavior by some bacterial spe-
cies and infection with new pathogens,78 
and also reviewed by Walk et al.102 The 
concepts of clinically relevant interactions 
between microbial community members, 
and further complication by antibiotics, 
have important implications for the CF 
lung where, once established, clinically 
significant pathogens are rarely eradicated 
despite frequent antibiotic treatment. 
Whilst the CF lung has been the focus 
of less work in this area, there are some 
examples of interspecies interactions that 
influence colonisation by clinically signifi-
cant pathogens. For instance, as patients 
acquire P. aeruginosa, S. aureus tends to 
be detected less frequently,103,104 although 
both species are commonly co-isolated.105 
A mechanism for this relationship has 
been suggested involving the production 
by P. aeruginosa of anti-staphylococcal 
substances, including 4-hydroxy-2-hep-
tylquinoline-N-oxide (HQNO), when 
co-infecting CF airways with S. aureus.104 
However, this compound also protects 
S. aureus during co-culture from com-
monly used aminoglycoside antibiotics.105 
Furthermore, it has been shown that pro-
longed growth of S. aureus with P. aerugi-
nosa selects for typical S. aureus small 
colony variants, which have stable amino-
glycoside resistance,106 and are persistent 
in chronic infections.107
Importantly, however, the presence 
of a particular species in the polymicro-
bial community of the CF airways or the 
gut is not necessarily sufficient to cause 
clinically evident disease. For example, 
pathogenic bacteria are able to exist in 
a carrier state, where the host does not 
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intercalates into extracellular DNA or 
into DNA in cells whose membrane integ-
rity has been lost. In contrast, PMA is 
excluded from intact cells. Subsequent 
exposure of a PMA-treated sample to a 
bright light source causes covalent cross-
links to form, rendering the extracellular 
or dead cell DNA unable to act as a PCR 
template. The application of this process 
has been shown to effectively limit down-
stream DNA-based processing to signals 
from viable bacterial cells alone, with its 
use demonstrated in the metagenomic 
profiling of the bacterial communities in 
the CF lung.8
Other confounding factors which 
should be considered when interpreting 
PCR-based microbial community analy-
ses are the biases introduced from primer 
selection, variations in nucleic acid extrac-
tion efficiencies between species, differ-
ential PCR amplification, the number of 
PCR cycles used, generation of chimeric 
sequences and the effect of rrn operon 
copy numbers and heterogeneity on diver-
sity estimates.137-140 In addition, although 
pyrosequencing has greatly enhanced our 
ability to monitor microbial communi-
ties, this technology throws up different 
challenges that must be addressed before 
analysing the data generated.141 The use of 
single reads as primary data, in combina-
tion with the intrinsic error rate of pyrose-
quencing, means that diversity estimates 
are artificially inflated, sometimes by sev-
eral orders of magnitude.142,143 On a posi-
tive note however, computational methods 
to remove these artefacts should greatly 
reduce this problem in the future.143
The consideration of these factors 
will greatly strengthen the data obtained 
through the metagenomic profiling of 
microbiota. The challenge that remains 
for the study both of chronic infections 
affecting CF airways and of gut microbi-
ota is to construct theoretical frameworks 
in which the implications of these data 
can be understood. To this end, studies 
that examine the behavior, and not just 
the species constituencies, of polymicro-
bial communities found in both healthy 
and diseased contexts, may help to con-
struct such models. Ultimately, however, 
combining the molecular approaches out-
lined above with careful epidemiological 
analysis in longitudinal, well-designed, 
provide a ready source of colonising agents 
for the CF lungs.134 However, as discussed 
here, the interrelationships between the 
microorganisms occupying these different 
areas of the body may also be mediated 
indirectly, through their interactions with 
the host.
The characterisation of the member-
ship and dynamics of the polymicrobial 
communities colonising areas such as the 
gut, oral cavity and skin is still in its rela-
tive infancy. Much of the complexity of 
these systems remains to be characterised, 
but technological advances, such as the 
development of next generation sequenc-
ing technologies, offer an opportunity 
to make significant gains in our under-
standing. These endeavours form part of 
a wider effort to construct an integrated 
“whole-body” view of the microbial com-
munities associated with healthy people 
over time.77 A natural progression of such 
an approach is to extend these nascent 
models to include pathogenic polymicro-
bial communities that exist within chronic 
infections, such as the CF lung.
There are, however, important meth-
odological considerations to be made 
when undertaking such work that, if 
ignored, have the potential to signifi-
cantly undermine the information that is 
derived. For example, in order to delin-
eate the links between the microbes that 
colonise a niche, such as the gut or the 
CF lung, and parameters of disease, it is 
essential that we are able not only to iden-
tify the species that are present, but also 
the dynamics of these microbial popula-
tions over clinically appropriate time-
frames. Culture-independent analysis in 
these contexts has typically involved the 
analysis of DNA extracted directly from 
a sample as a template for PCR amplifica-
tion. However, such analysis is unable to 
distinguish between live and dead bacte-
rial cells. Due to the persistence of DNA 
within clinical samples, such analyses 
may therefore be unable to detect rapid 
decreases in bacterial populations,135 with 
bias potentially being introduced due to 
variations between species in the period 
of retention of amplifiable DNA.136 One 
strategy that can be used to limit analy-
ses to viable cells is the use of propidium 
monoazide (PMA) treatment of samples 
prior to nucleic acid extraction.8 PMA 
species in the CF lung often behave less 
and less like traditional pathogens. This is 
illustrated by P. aeruginosa, where strains 
present in advanced CF infections differ 
substantially from “wild-type” P. aerugi-
nosa, with the counterintuitive loss of 
virulence factors required for acute infec-
tion,66,123 potentially resulting in a reduc-
tion in immune response.66,124 Therefore, 
the behavior of the bacteria present in the 
community may be as important as the 
identification of the species present, ren-
dering the clinical effects of antibiotics 
less predictable.
Importantly, the polymicrobial nature 
of the bacterial community infecting the 
CF lung or the gut microbiota may influ-
ence host immunity in a way that affects 
pathogenesis. For an example from the 
oral cavity, Streptococcus cristatus has 
been shown to be capable of dampening 
the IL-8 response induced by infection 
with Fusobacterium nucleatum in epithe-
lial cell culture. Using oral epithelial cells 
as a model, Mans et al.125 demonstrated 
that the degree of complexity of a mixed 
microbiota influenced the transcriptional 
response to infection of the epithelium. 
Thus, both the behavior of the microbiota 
and the host response can vary depending 
upon the complexity of the microbiota. In 
an example of potential relevance for the 
CF airway, species such as Streptococcus 
salivarius strain K12 have been shown 
to antagonise Pseudomonas aeruginosa-
induced IL-8 secretion from human bron-
chial epithelial cells. This again suggests a 
role for commensal species in modulating 
human epithelial cell immune responses 
in the nasopharynx and, potentially, other 
parts of the airway.126
Elucidating the Relationships  
Between the Host and Microbiota
Culture-independent techniques are 
increasingly being used to explore the bac-
terial content of locations in or on healthy 
individuals, such as the skin,77,127,128 the 
oral cavity,77,129,130 and the gut.77,131,132 
These microbial habitats do not exist in 
isolation, but form a microbial landscape 
interconnecting various niches in each 
individual.133 The physical links between 
the lower airways and areas such as the 
skin, oral cavity, and gastrointestinal tract 
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translational studies, will be necessary 
to generate these models. While in vitro 
models may afford new insights into the 
interactions between community mem-
bers and the host, and molecular studies of 
patient samples can provide a description 
of the complexity of these communities, 
the powerful marriage of clinical and lab-
oratory-based approaches will be required 
to more directly answer the question of 
how these communities influence human 
health and disease.
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